UK markets closed
NIKKEI 225
39,069.68 +282.30 (+0.73%) HANG SENG
19,636.22 +82.61 (+0.42%) CRUDE OIL
79.65 -0.15 (-0.19%) GOLD FUTURES
2,433.90 -4.60 (-0.19%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
54,811.17 +2,555.62 (+4.89%)
bioAffinity Technologies, Inc. (BIAF)
NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 2.2600 |
| Open | 2.2800 |
| Bid | 2.1900 x 100 |
| Ask | 2.2800 x 100 |
| Day's range | 2.1900 - 2.3000 |
| 52-week range | 0.9550 - 3.6200 |
| Volume | |
| Avg. volume | 260,737 |
| Market cap | 25.562M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
SAN ANTONIO, May 15, 2024--bioAffinity Technology reports record Q1 2024 revenue driven by accelerating sales of lung cancer diagnostic CyPath Lung.
- Business Wire
bioAffinity Technologies News Update
SAN ANTONIO, May 02, 2024--bioAffinity reports ramp in sales of CyPath® Lung, expanded sales team, new Patient Coach and upcoming presentation at American Thoracic Society.
- Business Wire
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
SAN ANTONIO, April 24, 2024--bioAffinity Technologies is developing diagnostics based on its proprietary platform for use with BAL fluid to detect lung cancer and to detect COPD.
© 2024 Yahoo. All rights reserved.